Because cladribine can increase cytarabine triphosphate levels, we tested a cladribine-cytarabine combination in the St Jude AML97, trial in which this combination was administered before standard chemotherapy to 96 children with acute myeloid leukemia (AML) or myelodysplastic syndrome. Patients received a 5-day course of cladribine (9 mg/m 2 per dose) and cytarabine either as daily 2-h infusions (500 mg/m 2 per dose) (arm A) or a continuous infusion (500 mg/m 2 per day) (arm B). Ara-CTP levels and inhibition of DNA synthesis increased from day 1 to day 2, but were not different between the two arms. In addition, the median blast percentages at day 15 did not differ between arms A and B, but patients treated in arm A had shorter intervals between the initiation of the first and second courses of therapy. Thus, although there were trends toward better complete remission rates and overall survival for patients treated in arm B, the reduced efficacy of arm A may have been partially compensated by more intense timing of therapy for that group. For all patients, 5-year event-free survival and overall survival estimates were 44.1 ± 5.4 and 50.0 ± 5.5%. Our results suggest that cladribine in combination with continuousinfusion cytarabine is effective therapy for childhood AML.
Introduction
Recent trials for childhood acute myeloid leukemia (AML) have attempted to improve cure rates by increasing cumulative doses of drugs, number of courses of therapy or intensity of blocks of treatment. 1, 2 However, results from most regimens are similar and novel drug combinations tried in previous trials have not improved event-free survival (EFS) rates, suggesting that a plateau in the benefit of conventional chemotherapy might have been reached. 3 An alternative approach is to combine selectively active agents that can enhance each other's efficacy. Cladribine (2-chlorodeoxyadenosine)Fa purine analogue that is intracellularly phosphorylated to its active formFinhibits DNA synthesis, causes cell death and induces apoptosis. 4, 5 We previously demonstrated that cladribine has significant antileukemic activity in patients with AML. [6] [7] [8] [9] Cytarabine, like cladribine, is converted to its active form by several phosphorylation steps. Cladribine increases the activity of deoxycytidine kinase, which catalyzes the first phosphorylation step. Administering cladribine before cytarabine to adults with AML increases accumulation of cytarabine triphosphate (ara-CTP) in leukemic cells. 10 Because cladribine shows antileukemic activity as a single agent, can augment ara-CTP levels and can be safely administered with cytarabine, [11] [12] [13] we initiated the AML97 trial, wherein the cladribine-cytarabine combination was administered before standard induction chemotherapy in children and adolescents with newly diagnosed AML. We present here the final results of this randomized clinical trial.
Patients and methods

Patients
From March 1997 to June 2002, 102 children with previously untreated AML or myelodysplastic syndrome (MDS) were enrolled in the St Jude AML97 trial. 14 All patients were younger than 22 years (median, 9.03 years; range, 0.05-21 years). Patients with acute promyelocytic leukemia were excluded, but those with all other subtypes of de novo or secondary AML, as well as patients with mixed-lineage leukemia, refractory anemia with excess blasts in transformation (RAEB-T) or Down's syndrome (DS, n ¼ 4) were eligible.
Therapy
Patients who agreed to participate in the upfront 'window' therapy were randomly assigned to receive either a daily short infusion of cytarabine (arm A) or a continuous infusion of cytarabine (arm B) ( Figure 1 ). 14 Patients in arm A received five daily 2-h infusions of cytarabine (500 mg/m 2 per day) and five daily 30-min infusions of cladribine (9 mg/m 2 ) that began 24 h after the start of the first cytarabine infusion. There was a 2-h interval between the end of each cladribine infusion and the start of each cytarabine infusion. Patients in arm B received cytarabine 500 mg/m 2 per day as a 120-h continuous infusion and five daily 30-min infusions of cladribine (9 mg/m 2 ), which began 24 h after the start of the cytarabine infusion.
Daunorubicin (30 mg/m 2 per day, continuous infusion, days 1-3), cytarabine (250 mg/m 2 per day, continuous infusion, days 1-5) and etoposide (200 mg/m 2 per day, continuous infusion, days 4 and 5) were the second and third courses of chemotherapy (DAV 1 and DAV 2). Patients with high-risk AML, that is, megakaryoblastic leukemia (M7), RAEB-T, secondary AML, -7, 5q-, t(9;22) or persistent leukemia after DAV 1, were eligible for allogeneic hematopoietic stem cell transplantation (HSCT) after DAV 2. Patients with t(8;21) or inv(16) were considered to have low-risk AML and were not eligible for allogeneic HSCT. All other patients were considered to have standard-risk AML and were eligible for HSCT if a matched sibling donor was available. From March 1997 to January 1999, patients not receiving allogeneic HSCT received unpurged autologous HSCT after receiving a conditioning regimen that consisted of busulfan (1 mg/kg orally every 6 h for 16 doses on days À9, À8, À7 and À6) and cyclophosphamide (50 mg/kg per dose on days À5, À4, À3 and À2). In January 1999, the protocol was amended to replace autologous HSCT with two courses of consolidation chemotherapy consisting of cytarabine (3 g/m 2 per dose every 12 h on days 1, 2, 8 and 9) and L-asparaginase (6000 U/m 2 per dose after the fourth and eighth doses of cytarabine), followed by mitoxantrone (10 mg/m 2 per dose on days 1-5) and cytarabine (1 g/m 2 per dose every 12 h on days 1-3).
Patients without central nervous system (CNS) disease received four monthly doses of age-adjusted intrathecal (IT) methotrexate, hydrocortisone and cytarabine (MHA), beginning day 15 from start of chemotherapy. Patients with CNS leukemia received weekly doses of IT MHA until the cerebrospinal fluid was clear of leukemia cells (minimum four doses) and then four monthly doses. In February 1999, the protocol was amended to include one dose of IT cytarabine during diagnostic procedures.
Response to cladribine-cytarabine was assessed by bone marrow aspirate and biopsy at day 15 from start of chemotherapy. Complete remission (CR) was defined as trilineage hematopoietic recovery with less than 5% blasts in the marrow, platelet count greater than 30 Â 10 9 per liter and absolute neutrophil count (ANC) greater than 0.3 Â 10 9 per liter. Complete response was defined as less than 5% blasts in the marrow without hematopoietic recovery. Patients with morphologic evidence of leukemia started DAV 1 immediately, whereas those without evidence of leukemia started DAV 1 when the platelet count was greater than 30 Â 10 9 per liter and the ANC was greater than 0.3 Â 10 9 per liter. Thus, patients with complete response at day 15 began DAV 1 when CR was attained.
Biology studies
In patients with X70% leukemic blasts in the bone marrow, pharmacokinetic and pharmacodynamic studies were performed as described previously. 14 Minimal residual disease (MRD) was measured by flow cytometry. 15 Briefly, leukemia-associated immunophenotypes were identified in diagnostic bone marrow specimens and marker combinations that allowed detection of 1 leukemia cell per 1000 mononuclear bone marrow cells were applied to subsequent samples. Results are reported at percentage of nucleated cells with the leukemia-associated immunophenotype. MRD negativity was defined as less than 1 leukemia cell per 1000 mononuclear bone marrow cells (that is, o0.1%).
Statistical plan and analysis
Our primary objective was to compare the ratio of ara-CTP concentration in leukemia cells after cladribine administration to that before cladribine administration across the two arms. The initial design called for randomization of 80 eligible patients with evaluable ara-CTP concentrations, allowed for one interim analysis and provided 80% power at the 5% level to detect a 40% difference in the change in ara-CTP concentrations between the two arms. In the interim analysis, we found the variance used for the initial study design to be inaccurate; 14 therefore, the planned sample size was adjusted to 52 patients per arm to give 80% power and an overall type I error rate of 5%.
The Wilcoxon rank-sum test was used to compare pharmacokinetic and pharmacodynamic variables by arm, amendment status or early IT therapy. The exact w 2 -test was used to compare clinical features, achievement of CR and MRD status across arms. The Kaplan-Meier method was used to compute estimates of EFS and overall survival (OS). The log-rank test was used to perform comparisons of EFS and OS distributions. EFS was defined as the time elapsed from study enrollment to study removal because of relapse, secondary malignancy or death, with those living and event-free censored as the time of last follow-up. OS was defined as the time elapsed from study enrollment to death. Multiple-variable Cox regression models were used to explore the association of early IT therapy with EFS and OS while accounting for initial leukocyte count, age and karyotype. Multiple-variable logistic regression models were used to explore the association of early IT therapy with achieving remission by the end of window therapy while accounting for initial leukocyte count, age and karyotype. Cox proportional hazards modeling was used to evaluate the prognostic relevance of age at diagnosis (as a continuous variable), initial leukocyte count (as a continuous variable), cytogenetics (favorable vs others), de novo status (de novo vs others) and presence of MRD (as a time varying covariate) on EFS and OS. No multiple-testing adjustments of P-values were performed. All analyses were performed by using the SAS software (SAS Institute, Cary, NC, USA), Windows version 9.1.3. Table 1 shows patient characteristics overall and by upfront treatment arm. Overall, 18% had low-risk karyotypes, and 25% had 11q23 abnormalities. Eighty-two patients had de novo AML, 11 treatment-related AML, 6 MDS-related AML and 3 mixedlineage leukemia. Patients in the two arms did not differ significantly by sex, race, age, initial leukocyte count, French-American-British (FAB) type, CNS involvement or presence of favorable cytogenetics, although nine patients had t(9;11) and two had normal karyotypes in arm A, whereas three patients had t(9;11) and thirteen had normal karyotypes in arm B (P ¼ 0.03).
Results
Patient characteristics
Response to upfront and remission induction therapy
Of the 102 patients, 50 were randomly assigned to arm A and 46 to arm B; 6 patients declined to participate in the upfront window therapy. More patients experienced grade 3 or 4 toxicity during upfront therapy in arm B than in arm A (48 vs 24%, P ¼ 0.019; Table 2 ). The two arms did not differ significantly in the number of patients experiencing toxicity during DAV 1 or DAV 2. Because we previously demonstrated that patients with monoblastic leukemia often respond well to cladribine, 9 we assessed the association between FAB and response to window therapy. Among all randomized patients, 13 of 17 (76%) of those with M5 AML achieved CR after window therapy, compared to 38 of 77 (49%) of non-M5 patients (P ¼ 0.059). The results were even more striking among randomized patients with de novo AML (11 of 13 (85%) vs 32 of 64 (50%), P ¼ 0.031).
Intracellular ara-CTP levels increased significantly from day 1 to day 2 (P ¼ 0.0002), but these increases did not differ significantly between arms (P ¼ 0.299); inhibition of DNA synthesis followed the same trend (data not shown). Despite the lack of significant differences in pharmacokinetic or pharmacodynamic parameters, patients in arm B were significantly more likely to achieve remission after upfront therapy (P ¼ 0.026 and 0.068 for all randomized and non-DS de novo patients, respectively) and induction I (P ¼ 0.008 and 0.077 for all randomized and non-DS de novo patients, respectively) than their counterparts in arm A ( Table 2 ). Remarkably, 44 of 46 (96%) patients in arm B achieved CR after only one course each of upfront therapy and DAV, compared to 38 of 50 (76%) in arm A. Although the two arms did not differ significantly with respect to MRD, EFS or OS, there was a trend toward better survival among patients in arm B than arm A (5-year OS 60.9 ± 7.2 vs 40.0±6.8%, P ¼ 0.069). It should be noted that potential outcome differences between the two arms may be confounded by differences in the timing of chemotherapy administration between arms. Although the median blast percentages at day 15 did not differ between arms A and B (5% for both arms), patients treated in arm A had shorter intervals between the initiation of the first course of therapy and the start of DAV 1 (median days, 18 for arm A vs 25 for arm B, P ¼ 0.008). Thus, it is possible that the reduced efficacy of arm A is partially compensated by more intense therapy for that group.
Overall treatment results Table 3 shows CR rates, causes of failure and death, EFS and OS for the 102 patients enrolled and the 78 non-DS patients with de novo AML. For all patients, 5-year EFS and OS estimates were 44.1 ± 5.4 and 50.0 ± 5.5% (Figure 2) , whereas corresponding estimates for patients without DS, secondary AML or MDS were 48.7 ± 6.3 and 53.8 ± 6.3%.
Of the 102 patients, 12 did not achieve CR: 10 had refractory leukemia and 2 died of disseminated Candida infections during induction therapy. Of the ten patients with refractory leukemia, three had treatment-related AML, two had MDS-related AML, two had mixed-lineage leukemia and three had de novo AML (one with megakaryoblastic leukemia, one with t(6;9) and one with monosomy 7). Of the 90 patients who achieved CR, 25 developed bone marrow or combined relapses (14 after chemotherapy, 5 after allogeneic HSCT, and 6 after autologous HSCT); there were no isolated CNS relapses. Of the 25 patients who relapsed, only 3 are alive. In addition, 15 patients (5 who received chemotherapy and 10 who received allogeneic HSCT) died in remission: 11 from infection (6 Aspergillus, 3 Candida, 1 Stenotrophomonas maltophilia, 1 Parainfluenza) and 4 from other complications related to allogeneic HSCT. The cumulative incidence of grade 3-4 toxicity was 84 ± 4% and of grade 3-4 infection was 61 ± 5%, with no significant differences in toxicities between treatment arms. The rates of grade 3-4 infection ranged from 26 to 38% after each course of chemotherapy.
We studied the associations between EFS and OS rates and potential prognostic factors: sex, race, cytogenetics, CNS involvement, MRD, FAB, age and leukocyte count at diagnosis (Table 4 ). MRD negativity after the cladribine-cytarabine upfront therapy was significantly associated with a higher EFS rate (P ¼ 0.029; Table 4 ), whereas MRD negativity after DAV 1 was significantly associated with higher OS (P ¼ 0.024) and EFS Table 4 should be interpreted with caution because of low patient numbers. In addition, favorable cytogenetics, de novo status, initial leukocyte count, age and the presence of MRD were found to be prognostically relevant factors for EFS in a multipredictor Cox regression analysis ( Table 5 ). Except for initial leukocyte count, the same factors were important for OS (Table 5 ). When MRD was excluded as a predictor to include patients without MRD data in the analysis, the impact of the remaining factors was found to be qualitatively similar as in Table 5 (data not shown).
Effects of amendments
The protocol underwent two major revisions that potentially affected clinical endpoints: autologous HSCT was replaced with two courses of chemotherapy and one dose of IT cytarabine before window therapy was added. Overall, there were no statistically significant differences in EFS (5-year estimates, 39.1 ± 7.0 vs 48.2 ± 6.7%, P ¼ 0.450) or in OS (5-year estimates, 43.5±7.1 vs 55.4±6.6%, P ¼ 0.249) between those treated before or after the amendments. Within each arm, there were no significant differences in the pre-and post-amendment cohorts with respect to sex, race, cytogenetics, CNS involvement, age, initial leukocyte count or FAB subtype. However, pre-amendment arm A patients were less frequently de novo than the other three therapy-defined groups (P ¼ 0.039). Among patients treated in arm A, those treated after the amendments had a slightly better EFS (5-year estimates, 50.0 ± 10 vs 27.3 ± 8.8%, P ¼ 0.091; Figure 2 ). In contrast, there were no differences in outcome among patients in arm B (Figure 2 ). In addition, preamendment arm A patients had a higher rate of relapse or induction failure than other patients (P ¼ 0.038). The 3-year estimates of cumulative incidence of relapse or induction failure for the four groups are as follows: arm A pre-amendment, 50.0±11.2%; arm A post-amendment, 28.6±8.8%; arm B preamendment, 25 ± 9.1%; arm B post-amendment, 31.2 ± 10.3%. Multiple-variable logistic and Cox proportional hazards regression models were used to explain the disparity of outcomes between pre-and post-amendment patients in arm A. Although the difference did not reach statistical significance, pre-amendment patients in arm A were less likely to achieve remission by the end of window therapy than post-amendment patients (P ¼ 0.099), even when adjusting for initial leukocyte count, age and karyotype. Also, for patients in arm A, treatment after replacing autologous HSCT with chemotherapy was significantly associated with better EFS (P ¼ 0.015), after adjusting for age, initial leukocyte count and cytogenetics.
Discussion
Results of this study demonstrate that cladribine administration can augment cytarabine pharmacokinetics and pharmacodynamics, The upfront window therapy consisted of daily cladribine with daily 2-h infusions of cytarabine (arm A) or with a continuous infusion of cytarabine (arm B). and the combination of cladribine and cytarabine can induce remission in over half of all patients. However, the CR rates of the present study cannot be directly compared with CR rates of other trials because of differences in the definitions of CR. Whereas most clinical trials define CR as less than 5% blasts in the marrow with a platelet count greater than 100 Â 10 9 per liter and an ANC greater than 1.0 Â 10 9 per liter, we defined CR as less than 5% blasts with a platelet count greater than 30 Â 10 9 per liter and an ANC greater than 0.3 Â 10 9 per liter. Nevertheless, despite an overrepresentation of t(9;11) in arm A (cladribine with short daily infusions of cytarabine), the combination of cladribine and continuous-infusion cytarabine (arm B) was more effective at inducing remission and appeared to contribute to a good overall outcome. Although our overall results were not better than those of other trials, the cladribinecytarabine combination might be particularly valuable for specific subgroups of patients, such as those with monoblastic leukemia. In contrast, the outcome for patients with t(8;21) was relatively poor (5-year OS, 36.4 ± 13.0%). This may reflect a lack of sensitivity of this subgroup of patients to the cladribinecytarabine combination, the absence of anthracyclines during the first course of therapy, the relatively low cumulative doses of anthracyclines or cytarabine, or the higher percentage of t(8;21) patients who received autologous transplant (27 vs 9.4%).
Replacing autologous HSCT with chemotherapy and adding early IT therapy appeared to favorably impact outcome, especially among patients who received cladribine with 2-h daily cytarabine infusions (arm A). Because these therapeutic changes were made in close proximity (January 1999 and February 1999), we cannot separate the effects of these interventions. However, the high relapse rate in patients after autologous HSCT suggests that the greatest effect was because consolidation chemotherapy was used. Nevertheless, the additional early IT therapy may have helped improve the CR rate in patients in arm A after protocol amendments. Effects of both changes were most pronounced among patients in arm A, probably because that regimen seems inferior to arm B.
Overall, the results of AML97 compare favorably with recently reported trials for childhood AML conducted in the United States. In the CCG-2961 trial, EFS and OS estimates were 42 and 52%, 2 whereas corresponding estimates from the Pediatric Oncology Group 9421 trial were 36 and 54%. 16 Contemporary European clinical trials for pediatric AML include the AML-BFM 98 trial (EFS, 49%; OS, 62%) 1 and trials reported by investigators from the Medical Research Council (EFS, 48%; OS, 56%), 17, 18 and the Nordic Society for Paediatric Haematology and Oncology (EFS, 49%; OS, 64%). 19 In our trial, which enrolled patients up to 22 years old with de novo AML, treatment-related AML and RAEB-T, the 5-year EFS and OS estimates were 44.1 and 50.0%, respectively. However, for patients with de novo AML, which represent a patient group similar to that treated on other cooperative group trials, the estimates are 48.7 and 53.8%; EFS and OS estimates after treatment amendments are even better (57 and 62%).
Cumulative doses of anthracyclines (430 mg/m 2 ) and cytarabine (35 g/m 2 ) for our patients who did not receive HSCT are similar to those for other trials. However, patients in AML97 had excellent CR rates with relatively modest doses (180 mg/m 2 ) of daunomycin during induction therapy. Also, outstanding CNS control (no isolated CNS relapses) was achieved in AML97 without using cranial irradiation. Although the follow-up is too short to describe late effects in detail, we have not observed any cardiac toxicity or secondary malignancies in AML97 survivors. However, we did observe unacceptably high rates of toxic deaths, especially among patients who underwent HSCT. As in some previous AML trials, [20] [21] [22] our patients had significant infection-related toxicity: 11 patients died of disseminated fungal infections (2 during remission induction and 9 who had achieved CR). To reduce this toxicity, we are currently testing prophylactic voriconazole in patients with AML. 23 In future studies, we will further explore the cytarabinecladribine combination as consolidation therapy in selected patients. Because it is unlikely that further refinements in conventional chemotherapy will improve outcomes for AML in a major way, we must focus instead on better understanding the biology of the disease, refining risk stratification, improving supportive care and developing alternative treatment approaches, including targeted therapy and cellular therapies.
